Latest Acadia Pharmaceuticals Inc (ACAD) Headlines
Acadia Pharmaceuticals Has Returned 14.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Tue Mar 11, 9:14AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.28% as of today's recent price of $28.44.
Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACADIA Pharmaceuticals prices public offering of 6.4m common shares
M2 - Wed Mar 05, 4:24AM CST
Biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) said on Tuesday that it has priced a public offering of 6,400,000 shares of its common stock.
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Mar 04, 6:28PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 960,000 shares of common stock. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.
ACADIA Pharmaceuticals plans to issue common stock in public offering
M2 - Tue Mar 04, 5:05AM CST
US-based biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) revealed on Monday that it intends to offer and sell USD150m of shares of its common stock in a public offering.
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Acadia Pharmaceuticals Shares Up 12.4% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Mon Mar 03, 10:02AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 12.44% as of today's recent price of $27.98.
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 10:55AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Business Wire - Thu Feb 27, 3:02PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Critical Alerts For Microsoft, GlaxoSmithKline, SunEdison, Acadia, and Family Dollar Released By InvestorsObserver
PR Newswire - Thu Feb 27, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MSFT, GSK, SUNE, ACAD, and FDO.
Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 26, 1:30PM CST
If you're caring for someone with Parkinson's disease or Alzheimer's, you should be watching Acadia Pharmaceuticals . Acadia plans to file its novel compound for Parkinson's psychosis, or PDP, later this year, a move which could significantly...
Shares of ACAD Up 18.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 24, 9:28AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 18.87% as of today's recent price of $29.58.
ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:18AM CST
ACADIA Pharmaceuticals Inc. (ACAD) was a big mover last session, as the company saw its shares rise by over 17% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 21, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Look for Shares of Acadia Pharmaceuticals to Potentially Pullback after Yesterday's 17.33% Rise
Comtex SmarTrend(R) - Fri Feb 21, 4:18PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $24.60 to a high of $29.50. Yesterday, the shares gained 17.3%, which took the trading range above the 3-day high of $24.75 on volume of 6.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch Out: Barbarians At The Gate For ACADIA Pharmaceuticals (ACAD)
at The Street - Fri Feb 21, 10:19AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
Business Wire - Thu Feb 20, 8:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, February 27, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
See What These $17 Billion Outperformers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon Feb 10, 4:35PM CST
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at Westfield Capital Management, an investment advisor serving...
Acadia Pharmaceuticals Has Returned 14.3% Since SmarTrend Recommendation (ACAD)
Comtex SmarTrend(R) - Tue Mar 11, 9:14AM CDT
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 14.28% as of today's recent price of $28.44.
Insider Trading Alert - ACAD, FOSL And GPRE Traded By Insiders
at The Street - Mon Mar 10, 11:16AM CDT
Stocks with insider trader activity include ACAD, FOSL and GPRE
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Wed Mar 05, 5:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following investor conferences:
ACADIA Pharmaceuticals prices public offering of 6.4m common shares
M2 - Wed Mar 05, 4:24AM CST
Biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) said on Tuesday that it has priced a public offering of 6,400,000 shares of its common stock.
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Mar 04, 6:28PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are expected to be $182.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 960,000 shares of common stock. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses.
ACADIA Pharmaceuticals plans to issue common stock in public offering
M2 - Tue Mar 04, 5:05AM CST
US-based biopharmaceutical company ACADIA Pharmaceuticals (NasdaqGS:ACAD) revealed on Monday that it intends to offer and sell USD150m of shares of its common stock in a public offering.
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Mar 03, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Acadia Pharmaceuticals Shares Up 12.4% Since SmarTrend's Buy Recommendation (ACAD)
Comtex SmarTrend(R) - Mon Mar 03, 10:02AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 12.44% as of today's recent price of $27.98.
ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today
at The Street - Fri Feb 28, 10:55AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
Business Wire - Thu Feb 27, 3:02PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013.
Critical Alerts For Microsoft, GlaxoSmithKline, SunEdison, Acadia, and Family Dollar Released By InvestorsObserver
PR Newswire - Thu Feb 27, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MSFT, GSK, SUNE, ACAD, and FDO.
Acadia Pharmaceuticals: Here's What You Should Know About Its Surging Shares
Todd Campbell, The Motley Fool - Motley Fool - Wed Feb 26, 1:30PM CST
If you're caring for someone with Parkinson's disease or Alzheimer's, you should be watching Acadia Pharmaceuticals . Acadia plans to file its novel compound for Parkinson's psychosis, or PDP, later this year, a move which could significantly...
Shares of ACAD Up 18.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Feb 24, 9:28AM CST
SmarTrend identified an Uptrend for Acadia Pharmaceuticals (NASDAQ:ACAD) on December 5th, 2013 at $24.89. In approximately 3 months, Acadia Pharmaceuticals has returned 18.87% as of today's recent price of $29.58.
ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:18AM CST
ACADIA Pharmaceuticals Inc. (ACAD) was a big mover last session, as the company saw its shares rise by over 17% on the day.
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 21, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Look for Shares of Acadia Pharmaceuticals to Potentially Pullback after Yesterday's 17.33% Rise
Comtex SmarTrend(R) - Fri Feb 21, 4:18PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $24.60 to a high of $29.50. Yesterday, the shares gained 17.3%, which took the trading range above the 3-day high of $24.75 on volume of 6.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch Out: Barbarians At The Gate For ACADIA Pharmaceuticals (ACAD)
at The Street - Fri Feb 21, 10:19AM CST
Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
Business Wire - Thu Feb 20, 8:00AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, February 27, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
See What These $17 Billion Outperformers Have Been Buying
Selena Maranjian, The Motley Fool - Motley Fool - Mon Feb 10, 4:35PM CST
Every quarter, many money managers have to disclose what they've bought and sold via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at Westfield Capital Management, an investment advisor serving...
